By pairing semaglutide with one or two experimental antibodies designed to preserve muscle, participants lost less lean body ...

New research compared the effect of semaglutide vs. tirzepatide on weight loss over a 72 week period. Here's what the study ...

Excess body weight can raise the risk of certain cancers, leading researchers to wonder whether blockbuster drugs like Wegovy, Ozempic ...

Participants who are taking GLP-1 medications and have taken them for at least 3 months are needed for a study on eating behavior.

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

Many folks in NC can’t access Ozempic due to limited insurance coverage. But policy changes and falling prices may expand ...

The findings presented at a conference in Chicago found a slightly lower risk of obesity-related cancers when adults with ...

Explore the evolving landscape of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obesity, highlighting access challenges and payer coverage trends affecting treatment options.

Despite her active and healthy lifestyle, Sasha Barden felt stuck in her weight loss journey. She decided to try GLP-1 ...

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...